Abstract

Since 2016 the UK Centre for Lead Discovery has been running
collaborative projects between AstraZeneca and academic researchers funded by
the MRC/CRUK. These projects have utilised the AZ compound collection and
high-throughput screening infrastructure to cover a wide range of target
classes, disease areas and assay technologies. We discuss the basis for the
UKCLD and two case studies which demonstrate the benefit of combining the
expertise of both industry and academia in identifying potential new starting
points for therapeutic targets.